See more : Firstsource Solutions Limited (FSL.NS) Income Statement Analysis – Financial Results
Complete financial analysis of Acumen Pharmaceuticals, Inc. (ABOS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Acumen Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Shenzhen Yinghe Technology Co., Ltd (300457.SZ) Income Statement Analysis – Financial Results
- Solis Minerals Ltd. (SLMN.V) Income Statement Analysis – Financial Results
- ServiceNow, Inc. (NOW) Income Statement Analysis – Financial Results
- Appen Limited (APXYY) Income Statement Analysis – Financial Results
- Seiryo Electric Corporation (4341.T) Income Statement Analysis – Financial Results
Acumen Pharmaceuticals, Inc. (ABOS)
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 1.44M | 1.70M |
| Cost of Revenue | 42.32M | 169.00K | 4.00K | 8.00K | 8.58K |
| Gross Profit | -42.32M | -169.00K | -4.00K | 1.43M | 1.69M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 99.44% | 99.49% |
| Research & Development | 42.32M | 32.36M | 12.31M | 8.00M | 8.58M |
| General & Administrative | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 18.82M | 12.88M | 7.28M | 1.35M | 926.00K |
| Other Expenses | 0.00 | -11.00K | 51.00K | 0.00 | 0.00 |
| Operating Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Cost & Expenses | 61.14M | 45.24M | 19.58M | 9.35M | 9.50M |
| Interest Income | 10.21M | 2.39M | 84.00K | 1.00K | 45.00K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | |
| Depreciation & Amortization | 184.00K | 169.00K | 4.00K | 7.91M | 7.81M |
| EBITDA | -51.61M | -42.69M | 61.58M | 587.00K | 119.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -591.78% | -451.27% |
| Operating Income | -61.14M | -45.24M | 61.57M | -7.91M | -7.81M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -550.97% | -459.93% |
| Total Other Income/Expenses | 8.77M | 2.38M | -81.02M | 587.00K | -102.00K |
| Income Before Tax | -52.37M | -42.86M | -100.61M | -7.33M | -7.91M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -510.10% | -465.94% |
| Income Tax Expense | 0.00 | -2.38M | 81.07M | -1.00K | -45.00K |
| Net Income | -52.37M | -40.48M | -181.68M | -7.32M | -7.86M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -510.03% | -463.29% |
| EPS | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| EPS Diluted | -1.08 | -1.00 | -4.49 | -0.18 | -0.20 |
| Weighted Avg Shares Out | 48.49M | 40.60M | 40.47M | 40.15M | 40.15M |
| Weighted Avg Shares Out (Dil) | 48.61M | 40.60M | 40.47M | 40.15M | 40.15M |
Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q1 2023 Earnings Conference Call May 9, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - Chief Medical Officer Matt Zuga - CFO and...
Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of...
Acumen Pharmaceuticals, Inc. (ABOS) Q4 2022 Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q4 2022 Earnings Conference Call March 27, 2023 8:00 AM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and Chief Executive Officer Eric Siemers - , Chief Medical Officer Matt Zuga...
Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023
CHARLOTTESVILLE, Va. and CARMEL, Ind., March 20, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer's disease, today announced that the...
Thales stärkt seine Führungsrolle beim eSIM-Management mit Google Cloud-zertifizierten und energieeffizienten Services
PARIS LA DÉFENSE--(BUSINESS WIRE)--Thales, der globale Marktführer im Bereich eSIM-Management, unterstützt das Wachstum von eSIM-fähigen Verbraucher- und Industriegeräten mit der Expertise von Google Cloud. Die bahnbrechende Cloud-Lösung von Thales kombiniert die eigenen Sicherheitsressourcen mit der Cloud-Präsenz von Google in 200...
Acumen Pharmaceuticals, Inc. (ABOS) CEO Daniel O'Connell on Q3 2022 Results - Earnings Call Transcript
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Alex Braun - Head IR Daniel O'Connell - President and CEO Eric Siemers - CMO Matt Zuga - CFO and CBO Conference...
Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022
CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimer's disease, today announced that the Company will report its financial...
Trading Ideas On The Upcoming CTAD 2022 Conference
The Clinical Trials on Alzheimer's Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen.
These Are the Five Best and Worst Performing Small-cap Stocks in September 2022
Small-cap stocks are usually young companies that aspire to become large-cap or mega-cap one day.
Why Is Acumen (ABOS) Stock Up 95% Today?
Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it's not due to any news from the company. Instead, investors have Biogen (NASDAQ: BIIB ) to thank for the increase of ABOS stock's price.
Source: https://incomestatements.info
Category: Stock Reports